Plain-English translation of NCT06584552 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether Lactobacillus Paracasei LPB27—a type of beneficial bacteria—can help reduce eczema symptoms in young children. The idea is that by improving the balance of healthy bacteria in your child's gut, the medication may help calm the immune system and reduce itching and dry skin. This is a Phase 2 study, meaning researchers are testing whether this approach actually works before moving to larger trials.
Eczema affects about 1 in 5 children and causes intense itching and dry skin that greatly affects quality of life. While steroid creams work well, many families are hesitant to use them regularly. Scientists have noticed that children with eczema have different gut bacteria than children without eczema, so this treatment aims to restore healthier bacteria to help prevent and treat eczema from the inside out.
You likely qualify if…
You likely don't qualify if…
You would give your child a small daily dose of the medication mixed into breast milk, formula, or solid food for 12 weeks. Half the children will receive the probiotic powder, and half will receive a placebo (a powder without the active ingredient) so researchers can fairly compare results. You'll need to stop any other probiotics your child is taking and keep detailed records of your child's eczema symptoms and overall quality of life during this time.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Australia
Phase
Testing effectiveness
Sponsor
The University of New South Wales
Collaborators
Evolution Health Pty Ltd
Enrollment target
~100 participants
Started
November 2024
Primary completion
March 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
3 Months – 3 Years
Last updated on clinicaltrials.gov in June 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Keith CY Ooi
University of New South Wales
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.